

CURRICULUM VITAE

May 2017

MIGUEL ANTONIO ESCOBAR, M.D.

PRESENT TITLE

Professor, University of Texas Health Science Center at Houston-McGovern Medical School
Professor, University of Texas M.D. Anderson Cancer Center
Medical Director, Gulf States Hemophilia & Thrombophilia Center

ADDRESS

University of Texas Health Science Center at Houston – McGovern Medical School
Gulf States Hemophilia & Thrombophilia Center
6655 Travis St. Suite #400
Houston, TX 77030

BIRTHDATE

Chicago, Illinois November 3, 1960

CITIZENSHIP

U.S.A.

UNDERGRADUATE EDUCATION

09/1978 – 06/1981 **California State Polytechnic University**
Pomona, California. (Biology)

GRADUATE EDUCATION

04/1982 – 01/1988 **Universidad Libre, School of Medicine, M.D.**
Cali, Colombia

POSTGRADUATE EDUCATION

01/1988 – 01/1989 **Hospital Universitario del Valle, Internship**
Cali, Colombia

02/1992 – 05/1993 **University of Miami, School of Medicine**
The William J. Harrington Latin American
Training Programs in Internal Medicine

07/1993 – 06/1996

University of Connecticut Health Center
Internal Medicine – Residency

07/1996 – 06/1999

University of North Carolina at Chapel Hill
Hematology/Oncology Fellow

ACADEMIC & ADMINISTRATIVE APPOINTMENTS

03/1989 – 03/1990

International Center for Medical Research and Training (CIDEIM), Cali, Colombia. Obligatory Social Service.

07/1990 – 01/1992

Universidad Libre, School of Medicine. Cali, Colombia. Adjunct Assistant Professor of Medicine

04/1990 – 01/1992

International Center for Medical Research and Training (CIDEIM), Cali, Colombia. Research Associate.

07/1999 – 06/2002

Clinical Instructor, University of North Carolina at Chapel Hill. Department of Hematology/Oncology

07/2002 - 08/2008

Assistant Professor of Medicine and Pediatrics. University of Texas Health Science Center, Houston

07/2002 – 2008

Associate Medical Director, Gulf States Hemophilia and Thrombophilia Center, Houston

07/2002 – present

Director, Research Laboratory, Gulf States Hemophilia & Thrombophilia Center (GSHTC)

09/2008 – 08/2014

Associate Professor of Medicine and Pediatrics (Tenure). University of Texas Health Science Center, Houston

01/2009 - present

Medical Director, Gulf States Hemophilia and Thrombophilia Center, Houston

2011 – 08/2016

Co-Director, Clinical Research Center, UTHSC

09/2014 – present

Professor of Medicine and Pediatrics (Tenure). University of Texas Health Science Center, Houston

09/2016 – present

Director, Clinical Research Center, UTHSC

HOSPITAL APPOINTMENTS

2002 – present	Attending Physician, Department of Pediatrics and Internal Medicine, Memorial Hermann Hospital, Houston, TX
2002 – present	Attending Physician, Department of Pediatrics and Internal Medicine, LBJ Hospital, Houston, TX
2002 – present	Attending Physician, Department of Pediatrics and Bone Marrow Transplantation, M.D. Anderson Cancer Center, Houston, TX
2002 – present	Staff, Provisional Category, Providence Memorial Hospital, El Paso, TX
2008 – 2014	Director, Outpatient Anticoagulation Service, Memorial Hermann Hospital
2015 – present	Director of Medication Therapy and Wellness Center, Memorial Hermann Hospital

LICENSURE

Texas L5325 Exp: 05/31/2017

CERTIFICATION

Hematology	# 167791	2004
Internal Medicine	# 167791	1996
FLEX	# 601103507	1993
ECFMG	# 0-417-172-4	1992

PROFESSIONAL ORGANIZATIONS

National:

American Society of Hematology since 1997

International:

The International Society of Thrombosis and Haemostasis since 1998

World Federation of Hemophilia 2002, 2012-2014

Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis (CLAHT) since 2013

HONORS AND AWARDS

California State Polytechnic University, Pomona, California

Dean's honors list: Fall/79, Fall/80, Winter/81

Universidad Libre, School of Medicine. Cali, Colombia

Dean's honor list: I, IV, V, VI, VII semesters

Best student award scholarship: V, VII semesters

First in graduating class 1989

Cartamedas Organization Scholarship 1989

Colombian National Science Award: Fundacion Alejandro Angel Escobar. 1993

Harold N. Willard, M.D. Award. Excellence in Ambulatory Care. The University of Connecticut Internal Medicine Residency Program. 1995 – 1996

Dean's Teaching Excellence Award. Univ of Texas Health Science Center. 2012, 2013, 2014

EDITORIAL POSITIONS

07/1999 - 07/2002	Advisory Board, <u>Haemostasis and Thrombosis</u>
01/2000 to 2008	Editorial Board, <u>Hemophilia Forum</u>
06/2005 to present	Advisory Board, <u>The International Monitor in Hemophilia</u>
2008 to present	Review articles for Haemophilia, Journal of Thrombosis and Haemostasis, Blood
2011 – 2015	Review abstracts for International Society of Thrombosis and Hemostasis annual meeting
2011 - 2012	Review abstracts for the American Society of Hematology annual meeting

SERVICE ON GRADUATE SCHOOL COMMITTEES

2004 - 2008	Advisory/Supervisory Committee of Graduate Students, UT Graduate School of Biomedical Sciences
-------------	------------------------------------------------------------------------------------------------

SERVICE ON UT-HMS AFFILIATED HOSPITAL COMMITTEES

2002 - present	Chair, Research Committee, GSHTC
2002 - present	Chair, Pharmacy Hemostasis Committee, Memorial Hermann Hospital System
2007 - present	Chair, Patient Blood Management Committee, Memorial Hermann Hospital
2009 - present	Member of Hematology/Oncology Subcommittee, Lyndon B. Johnson and Ben Taub Hospitals
2014 - present	Member of the LBJ Clinical Research Advisory Committee
2017 – present	Member of the JOC Venous Thromboembolism Reduction Committee, Memorial Hermann Hospitals

SERVICE TO THE COMMUNITY

1999 – present	Volunteer for the World Federation of Hemophilia (WFH)
2002 – present	Attending Physician, Women with Bleeding Disorders Camp, Texas
2002 – present	Member, Hemophilia Consumer Advisory Board, Houston TX
2002 – present	Satellite Hemophilia Clinic, Providence Hospital, El Paso, TX
2006 – 2010	Member of the International Hemophilia Treatment Centers Committee for the World Federation of Hemophilia
2007 – 2010	Coordinator, WFH Twinning Program GSHTC and El Salvador
2008 – 2009	Attending Physician, National Youth Leadership Institute Camp (NHF), Texas
2009 - 2013	Medical Director of Hemophilia Camp Ailhpomeh, Texas
2009 - 2016	Advisor for the Ministries of Health of El Salvador, Honduras, Dominican Republic and Ecuador for the development of guidelines for diagnosis and treatment of hemophilia
2009 – present	Medical Advisor for the Lone Star Hemophilia Chapter, Texas
2012 – 2015	Chair of the Texas Bleeding Disorder Advisory Council
2015	Advisor for the Ministry of Health of Colombia (Cuenta de Alto Costo Program) for the development of outcomes for diagnosis and treatment of hemophilia
2012 – 2016	Member of the International Hemophilia Treatment Centers Committee for the World Federation of Hemophilia
2016 – 2018	Chair of the International Hemophilia Treatment Centers Committee for the World Federation of Hemophilia
2016 – 2018	Member of the World Federation of Hemophilia Education Advisory Committee
2016 – 2020	Member of the Blood Products Advisory Committee of the Food and Drug Administration (FDA).

SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE

2004-2008	Mentor, Stephanie Planque, PhD. Pathology Department
2012-2013	Mentor, Bradley A Rolf. Genetics Department

NEW INVESTIGATOR DEVELOPMENT PROGRAM

2011-2012	Mentor, Modupe Idowu, M.D. Hematology Department
-----------	--------------------------------------------------

SPONSORSHIP OF POSTDOCTORAL FELLOWS

2003-2006	Mentor, Nidra Rodriguez, MD, Hematology/Oncology Fellow
-----------	---------------------------------------------------------

CURRENT TEACHING RESPONSIBILITIES

I. International Hemophilia Training Centre Mentor

07/2002	Dr. Loretta Buchner, Hematologist from Jamaica
07/2003	Dr. Patricia LeForte, Hematologist from Chile
07/2005	Dr. Gloria Chumpitaz, Hematologist from Peru
07/2007	Dr. Carmen Miranda, Physiatrist from Mexico
07/2007	Dr. Cecilia Piotrowski, Physiatrist from Chile
07/2009	Cecilia Melendez, Registered Nurse from El Salvador
08/2010	Maritza Diaz Alvarenga, Licensed PT/OT from El Salvador
10/2010	Mariany Zulema Guerra, lab technician from Panama
08/2012	Vaneska Caballero, Nurse from Nicaragua
06/2013	Gloria Ceballo, Lab technician from Panama
07/2013	Dr. Roya Dolatkah, Hematologist from Iran
08/2014	Mario Portuguez & Claudia Farfan, lab technicians from Mexico
02/2015	Johana Ordoñez (Nurse) & Sara Juarez (PT) from Honduras
03/2015	Walter Sosa, lab technician from Honduras
04/2015	Dr. Kenia Miller (Panama) and Dr. Lora Villareal (Mexico)
08/2015	Dr. Ana Bastardo from Venezuela
09/2015	Dr. Gisela Barrios from Colombia
04/2017	Dr. Natalia Padilla from Mexico

2011 – present International Training course for Latin American Hematologists

II. Supervisory Teaching

Direct Supervision:

Mentor, Mariam Abdullatif, First Year Medical Student, NIH grantee for the 2005 Summer Research Program of the University of Texas Health Science Center at Houston
 Direct Supervision, Medical Students, Hematology Rotation
 Direct Supervision, Residents, Hematology Rotation
 Direct Supervision, Fellows, Hematology Rotation
 2006-2007 Clinical Preceptorship Program for the Physical Diagnosis Course

III. Core Curriculum Program. First Year Medical students

2004-2017 Bleeding and Clotting Disorders

IV. MS III Internal Medicine Clerkship

2004 – 2017 Bleeding and Clotting Disorders

V. Hematology Lectures

Medical Students and IM Residents: University of Texas Health Science Center at Houston
 2003-2017 Venous Thromboembolism
 Assessment of the Bleeding Patient

Hematology Fellows Lectures: University of Texas Health Science Center at Houston:

2003-2017 Hemophilia and other coagulation deficiencies
Venous Thromboembolism
Acquired Inhibitors

Cardiovascular Fellows Lectures: University of Texas Health Science Center at Houston

2007-2014 Hemostasis in cardiovascular surgery
Platelet abnormalities in cardiovascular surgery
New concepts of coagulation

Hematology Fellows Lectures: Baylor College of Medicine at Houston

2008-2017 The Hemophilias and other Factor Deficiencies

Grand Rounds: University of Texas Health Science Center at Houston

05/2004 "Remodeling the Coagulation Cascade – Simplifying the Complex", Internal Medicine
09/2004 "Update on Hemophilia and Factor VIIa Therapy", Department of Anesthesiology
12/2004 "Hematologic Emergencies", Department of Family and Community Medicine
12/2005 "New Concepts of Coagulation", Department of Anesthesiology
07/2006 "Hematologic Emergencies", Department of Family and Community Medicine
09/2006 "Recombinant Factor VIIa", The Second Annual Frank M. Yatsu Stroke Symposium
02/2007 "Challenges in the Use of Recombinant FVIIa", Department of Cardiothoracic & Vascular Surgery
03/2008 "Management and Monitoring of Oral Anticoagulants", Department of Family and Community Medicine
05/2009 "Venous Thromboembolism", Department of Internal Medicine
06/2009 "Venous Thromboembolism", Department of Emergency Medicine
04/2010 "Heparin Induced Thrombocytopenia" Department of Cardiovascular Surgery
04/2011 "Heparin Induced Thrombocytopenia Diagnosis and Management", Department of Cardiology
06/2011 "Hemophilia and Aging: Challenges and Implications for Future Care". Department of Internal Medicine.
06/2012 "New Concepts in Coagulation", Department of Neurology and Neurosurgery.

12/2012 “Sugar and Spice and not Everything Nice: New Anticoagulants “, Department of Internal Medicine.

08/2013 “New Oral Anticoagulants”, Division of Cardiology.

04/2014 “Appropriate Use of Blood Components in a Modern Acute Care Hospital” Memorial Hermann Hospital Grand Rounds. Houston, TX.

09/2014 “Blood Utilization Program” House Staff Association Lecture, Memorial Hermann Hospital, TMC.

01/2017 “New Treatment Strategies for the Treatment of Bleeding Disorders”, Department of Anesthesiology.

03/2017 “New Treatment Strategies for the Treatment of Bleeding Disorders”, Department of Internal Medicine

National Grand Rounds:

04/2003 “New Concepts of Coagulation”, Hematology/Oncology, University of Alabama at Birmingham, AL

11/2003 “Surgical Bleeding, Trinity Medical Center, Carrollton, TX

02/2004 “Medical and Surgical Bleeding”, Bryce Hospital, Tuscaloosa, AL

07/2004 “Surgical Bleeding”, Yampa Valley Medical Center, Steamboat Springs, Colorado

06/2005 “Congenital Hemophilia and Inhibitors”, Lee Moffitt Cancer Center, Tampa, Florida

02/2007 “New concepts of coagulation” and “Transfusions in children”, Ciudad Juarez, Mexico. XXI Jornadas Bi-Nacionales de Pediatria/Texas Tech University Health Science Center

09/2007 “Managing/Monitoring Bleeding Complications”, The Southeastern College of Anticoagulation Providers in conjunction with The University of Tennessee Health Science Center Colleges of Pharmacy and Nursing, Franklin, TN

01/2008 “Challenges in the Therapeutic use of Hemostatic Agents in the Acute Care Setting”. St. Christopher’s Hospital for Children, Philadelphia

02/2009 “Factor Replacement in Bleeding Disorders: What is the best dose and duration of therapy”. Hematology Grand Rounds, Texas Children’s Hospital. Houston, Texas

08/2011 “Transition of hemophilia patients to the adult world-what are the challenges?”. Hematology Grand Rounds, Texas Children’s Hospital. Houston, Texas

07/2012 “Management of Patients with Rare Bleeding Disorders” Department of Oral and Maxillofacial Surgery. The Methodist Hospital. Houston, Texas.

04/2015 "Prophylaxis in hemophilia. New therapeutic options". Hospital of Cook County. Hematology Grand rounds. Chicago, Illinois.

04/2015 "Treatment Options for prophylaxis in hemophilia". Hematology grand Rounds. Texas Children's Hospital. Houston, TX.

04/2015 "Prophylaxis in hemophilia. New Therapeutic options". Hematology Grand rounds. Children's Hospital at Memorial University Medical Center. Savannah, GA.

CURRENT GRANT SUPPORT

A cross sectional analysis of CV disease in the Hemophilia Population-ATHN1 Extension
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: American Thrombosis and Hemostasis Network
Award Period: 09/30/2015-09/29/2019

A Randomized, Multicenter, Open-label, Phase III Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Prophylactic RO5534262 with Episodic Bypassing Agents vs. no Prophylaxis with Episodic Bypassing Agents in HA Patients with Inhibitors.
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: Genentech, Inc.
Award Period: 12/01/2015-07/21/2018

Plasma/Albumin-Free-Method (rAHF-PFM): A Phase 4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the efficacy and Safety of Continuous Infusion (CI) Versus Intermittent bolus Infusion (BI) in subjects with severe or moderately severe Hemophilia A undergoing unilateral primary Total Knee Replacement
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: Baxalta Inc.
Award Period: 01/21/20/-12/31/2020

An observational study of Postoperative Deep Venous Thrombosis (DVT) in Hemophiliacs Undergoing Major Orthopedic Surgery.
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: University of North Carolina, Chapel Hill
Award Period: 10/11/2013-10/26/2017

Hemophilia Utilization group Studies Part VI (HUGS VI)
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: University of Southern California
Award Period: 03/27/2015-03/26/2022

Hemophilia Utilization Group Studies Part VI (HUGS VI): An Adherence study among participants with Hemophilia.
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: University of Southern California
Award Period: 09/22/2014-05/31/2016

A phase 1/2A, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant Factor VIIA (MOD-5014) in adult men with hemophilia A or B.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: OPKO Biologics, Ltd.

Award Period: 05/21/2015-06/01/2016

AskBio0009- 101 adult hemophilia: A phase ½ open-label, single ascending dose trial of a self-complementing optimized adeno-associated virus serotype 8 Factor IX therapy (AskBio0009) in adults with severe hemophilia B

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Baxalta Inc.

Award Period: 04/09/2013-04/08/2018

A phase III open label, multicenter, extension study to assess the safety and efficacy of recombinant coagulation factor VIII (rIII-single-chain, CSL627) in subjects with severe hemophilia A.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: CSL Behring

Award Period: 10/10/2014-12/31/2019

Factor VIII Fusion (rFVIIIIFc) in the prevention and treatment of bleeding episodes in previously treated subjects with Hemophilia A

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Biogen Idec MA, Inc.

Award Period: 06/04/12-03/20/2018

Study of prophylaxis, activity and effectiveness in Hemophilia patients currently treated with Advate or Rixubis.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Baxalta Inc.

Award Period: 02/11/2015-02/10-2020

Safety and Efficacy of NNC-0156-0000-0009 after long term exposure in patients with Haemophilia B.

Principal Investigator Univ Texas: Miguel A. Escobar, MD

Funding Agency: Novo Nordisk

Award Period:08/22/2012-04/30/2016

Antihemophilic Factor (Recombinant), Plasma/Albumin-Free-Method (rAHF-PFM): A phase 4, prospective, controlled, randomized, multi-center study to compare the efficacy and safety of continuous infusion (CI) versus intermittent bolus infusion (IB) in subjects with severe or moderately severe Hemophilia A undergoing unilateral primary total knee replacement.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Baxalta Inc.

Award Period: 01/21/2008-12/31/2020

Prospective, open-label, multi-center, phase III clinical study to investigate the efficacy and safety of human factor VWF/VIII concentrate (Wilate®) in subjects with inherited type 3 von Willebrand Disease (VWD) who undergo major surgical procedures.

Co-Principal Investigator Univ Texas: Miguel A. Escobar, MD

Funding Agency: Octapharma AG.

Award Period: 12/14/2011-06/30/2017

Phase II/III partial randomized, open label trial comparing prophylactic treatment with BAY 94-9027 (at once and twice a week dosing to on demand infusion).

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Bayer Healthcare

Award Period: 01/24/2012-01/23/2017

A phase I/III open-label, multicenter, crossover safety, efficacy and pharmacokinetic study of recombinant coagulation Factor VIII (rFVIII) compared to recombinant human antihemophilic Factor VIII (rFVIII; INN:octocog alfa) in subjects with Hemophilia A and repeat PK, safety and efficacy study.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: CSL Behring

Award Period: 03/21/2013-03/20/2018

An open-label, multicenter evaluation of the long-term safety and efficacy of recombinant human coagulation Factor VIII fusion protein (rFVIII-Fc) in the prevention and treatment of bleeding episodes in previously treated subjects with Hemophilia A.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Biogen Idec MA, Inc

Award Period: 06/04/2012-04/30/2016

A phase 3, prospective, open-label study to evaluate safety and efficacy of recombinant activated FVII B1 (rFIIa B1) in the treatment of acute bleeding per an on-demand regimen in patients with hemophilia A or B with Inhibitors.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Baxalta Inc.

Award Period: 06/28/2013-06/30/2016

PAST GRANT SUPPORT

A phase 3, prospective, open-label, randomized study to evaluate safety and efficacy of rFVIIa BI (Bax817) in the treatment of acute bleeding episodes per an on-demand regimen in patients with Hemophilia A or B with inhibitors.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Baxter Innovations GmbH

Award Period: 06/28/2013-06/27/2015

Study of inspiration's recombinant factor IX product, IB1001, in previously treated pediatric subjects with Hemophilia B.

Co-Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Inspiration Biopharmaceuticals, Inc.

Award Period: 05/27/2011-05/26/2016

Hemophilia Capacity Grant

Principal Investigator: Miguel A. Escobar, M.D.

Funding Agency: National Hemophilia Foundation

Award Period: 10/01/2013-09/30/2015

A multi-national trial evaluating safety and efficacy, including pharmacokinetics of NNC 0129-0000-1003 when administered for treatment and prophylaxis of bleeding in patients with Haemophilia A.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Novo Nordisk

Award Period: 07/30/2012-08/31/2015

A phase II/III, randomized, cross-over, open-label trial to demonstrate superiority of prophylaxis over on-demand therapy in previously treated subjects with severe hemophilia A treated plasma protein-free recombinant FVIII formulated with sucrose.

Principal Investigator Univ. Texas: Miguel A. Escobar, M.D.

Funding Agency: Bayer Healthcare Corp.

Award Period: 09/20/2010-09/30/15

The pathophysiology of anti-factor VIII inhibitor development in patients with hemophilia A undergoing surgery.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Emory University

Award Period: 03/08/2011-02/28/2015

A cross-sectional analysis of cardiovascular disease in the hemophilia population

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: American Thrombosis and Hemostasis Network

Award Period: 09/30/2011-09/29/2015

Efficacy and safety of NNC 0129-0000-1003 during surgical procedures in patients with Haemophilia A

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Novo Nordisk

Award Period: 11/02/2012-11/01/2014

Phase I, II, III pharmacokinetics and outcome study of Inspiration's Recombinant Factor IX product, IB1001, in subjects with Hemophilia B Protocol No. IB1001-01.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Rho, Inc

Award Period: 10/12/2009-09/30/2014

Universal data and serum specimen collection system for Hemophilia
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: CDC.
Award Period: 07/01/2010-09/30/2014

iBleed-An application for calculating and monitoring factor levels among persons with severe Hemophilia A or B
Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Pfizer
Award Period: 12/01/2011-12/31/2014

Hemophilia Inhibitor Genetics Study (HIGS)
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: Rho, Inc.
Award Period: 07/29/2003-03/31/2014

A Study of Immunologic Safety for Alphanate® in Previously Treated Patients Diagnosed with Hemophilia A.
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: Grifols Biologicals, Inc.
Award Period: 03/31/2006-08/31/2014

Safety, efficacy & pharmacokinetics of NNC-0156-000-00009 in previously treated children with Haemophilia B.
Principal Investigator: Miguel A. Escobar, MD
Funding Agency: Novo Nordisk
Award Period: 08/21/2012-04/30/2014

A multi-centre, single-blind trial evaluating safety and efficacy, including pharmacokinetics, of NNC-0156-0000-0009 when used for treatment and prophylaxis of bleeding episodes in patients with Haemophilia B.
Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Novo Nordisk
Award Period: 02/01/2012-01/31/2014

An open-label, multi-centre, uncontrolled trial to assess efficacy and safety of NNC-0156-0000-0009 during surgical procedures in patient with Haemophilia B
Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Novo Nordisk
Award Period: 08/03/2012-04/30/2014

Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe Hemophilia A adult subjects compared to that of episodic treatment – SPINART.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Bayer

Award Period: 7/2/2008-6/30/2014

A phase III, open multi-center study to investigate the pharmacokinetics, safety and efficacy of BPLs high purity Factor X.

Principal Investigator: Miguel A. Escobar, M.D.

Funding Agency: BioProducts

Award Period: 05/10/2012-03/10/2014

Phase I/II, prospective, dose-escalation/finding study to evaluate pharmacokinetics and immediate tolerability of Recombinant activated Factor VII (rFVIIa BI) in patients with Hemophilia A or B and inhibitors.

Principal Investigator: Miguel A. Escobar, M.D.

Funding Agency: Baxter Healthcare Corporation

Award Period: 08/09/2010-08/31/2013

A-Long: Factor VIII Fc Fusion (rFVIIIFc) in the prevention and treatment of bleeding in previously treated subjects with severe hemophilia A.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Biogen Idec Hemophilia, Inc

Award Period: 06/16/2011-09/30/2013

B-Long: Open label, multicenter evaluation of the safety, pharmacokinetics, efficacy of recombinant, long-acting coagulation factor IX Fe fusion protein (rFIXFc) in the prevention and treatment of bleeding in previously treated subjects with hemophilia B.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Biogen Idec Hemophilia, Inc

Award Period: 03/04/2011-02/28/2013

Public Health Surveillance for the prevention of complications of bleeding and clotting disorders in HTC's.

Co-Principal Investigator: Miguel A. Escobar, MD

Funding Agency: CDC

Award Period: 09/30/2011-09/29/2012

Prospective ADVATE Immune Tolerance Induction Registry (PAIR)

Principal Investigator Univ. Texas: Deborah Brown, MD

Co-Principal Investigator: Miguel A. Escobar, M.D.

Funding Agency: Baxter Healthcare Corp.

Award Period: 08/21/2007-12/31/2012

Pilot study for standardization of diagnostic techniques for central venous thromboembolism study

Co-Principal Investigator: Miguel A. Escobar, M.D.

Funding Agency: Bristol-Myers Squibb

Award Period: 06/20/2011-06/19-2012

A multi-national open-label, dose escalation trial evaluating safety and pharmacokinetics of intravenous doses of NNC 0129-000-1003 in patients with Hemophilia A

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Novo Nordisk

Award Period: 03/01/2011-02/28/12

An Open-label, randomized, multi-center phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin derivatives in subjects requiring emergency surgery or invasive diagnostic intervention.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: CSL Bering .

Award Period: 04/23/2009-04/22/2012

An Open-label randomized, multi-center Phase IIIb study to access efficacy, safety, and tolerance of BERIPLEX P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin derivatives in subject with acute major bleeding.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: CSL Behring

Award Period: 12/1/2008-12/31/2012

A randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis treatment with rFVIII-FS in previously treated patients with severe hemophilia A.

Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: Bayer Pharmaceuticals, Inc

Award Period: 02/01/2009-01/31/2011

Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A: The RICH Study

UTHSCH Principal Investigator Univ Texas: Miguel A. Escobar, M.D.

Funding Agency: National Heart, Lung and Blood Institute

Award Period: 08/30/2006-08/29/2010

Covalent Inactivation of Antibodies to Factor VIII.

Principal Investigator: Miguel A. Escobar, M.D.

Funding Agency: Hemophilia of Georgia, Inc.

Award Period: 05/01/2005-06/30/2010

Latin American Training and Inhibitor Network (LATIN)
Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Novo Nordisk Hemophilia Foundation
Award Period: 01/01/2008-06/30/2010

Recombinant Antihemophilic Factor Manufactured and Formulated Without added Human or animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy and Safety in Previously Untreated Patients with Hemophilia A.
Principal Investigator Univ Texas: Deborah Brown, MD
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Baxter Healthcare Corporations
Award Period: 05/19/2004-12/31/2009

Risk Factors for Inhibitor Development in Mild or Moderate Hemophilia A
UTHSCH Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: Emory University School of Medicine
Award Period: 04/05/2007-06/30/2009

Adaptive Hemostatic Responses in Patients with Severe Hemophilia A
Principal Investigator: Deborah Brown, MD
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: University of Texas Health Science Center at Houston, Department of Pediatrics Research Committee
Award Period: 09/01/2007-08/31/2009

Parents Empowering Parents
Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Chandler Chico Agency
Award Period: 01/21/2008-06/15/2009

An Open Label Multi-Center Elective Surgery Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients with Hemophilia A
Principal Investigator: W. Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Wyeth Pharmaceutical
Award Period: 01/01/2006-12/31/2008

A Prospective, Randomized, Cross-Over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients with Hemophilia A and Inhibitors (ProFeiba)
Principal Investigator: Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Baxter BioScience: Tulane University Health Sciences Center
Award Period: 04/21/2006-12/31/2008

Hemophilia and Thrombosis Research Society Registry
Principal Investigator: Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: HTRS Registry
Award Period: 09/22/2004-09/21/2008

An Open Label Study of the Hemostatic Activity, Pharmacokinetics and Safety of OBI-1 (B-Domain Deleted Recombinant Porcine FVIII) When Administered by Intravenous Injection to Control Non-Life and Non-Limb Threatening Bleeding Episodes in Congenital Hemophilia A Patients with an Inhibitor Human FVIII.
Principal Investigator Univ Texas: Miguel A. Escobar, M.D.
Funding Agency: Octagen Corporation
Award Period: 09/01/2005-10/23/2008

A Randomized Two-Way Blinded Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) with a Full-Length Recombinant Factor VIII Preparation (FLrFVIII, Advate) Followed by an Open-Label Trial of the Safety and Efficacy of ReFacto AF in Previously Treated Patients with Hemophilia A.
Principal Investigator: W. Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Wyeth Pharmaceuticals
Award Period: 04/06/2005-04/05/2007

Covalent Tolerance Induction to FVIII. Supported by: Hemophilia Assoc. of New York, Inc.
Principal Investigator: Sudhir Paul, Ph.D.,
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Hemophilia Association of New York (HANY)
Award Period: 04/01/2005-03/31/2007

A Randomized Prospective Study for the Prevention of Joint Disease in Children with Factor VIII Deficiency.
UTHHSC Principal Investigator: W. Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Centers for Disease Control and Prevention/University of Colorado Health Sciences Center
Award Period: 09/30/1996-09/29/2006

Evaluation of Hemostasis in Bleeding and Thrombotic disorders using the ROTEG analyzer.
Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Novo Nordisk A/S
Award Period: 07/01/2003-06/30/2006

An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as I.V. Bolus or I.V. Continuous Infusion to Hemophiliacs with Inhibitors During and After Major Surgery.
Principal Investigator: W. Keith Hoots, M.D.,

Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Novo Nordisk Pharmaceuticals.
Award Period: 06/07/1998 – 01/31/2006

A multicenter study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital hemophilia A who develop de novo factor VIII inhibitors while receiving factor VIII infusion therapy,
Principal Investigator: W. Keith Hoots, M.D
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Wyeth Pharmaceuticals
Award Period: 06/13/2005-06/12/2006

Assessing Concerns with Safety of Hemophilia Products: Patient and Parent Focus Groups
Principal Investigator: Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Research Triangle Institute
Award Period: 06/06/2005-11/28/2005

The FEIBA NovoSeven Comparative Study (FENOC)
Principal Investigator: Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Award Period: 07/01/2004-12/31/2005

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P) Using Individualized Dosing in Pediatric and Adult Surgical Patients with von Willebrand's Disease.
Principal Investigator: W. Keith Hoots, M.D.,
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Aventis Behring
Award Period: 06/01/2003 – 12/31/2005

Phase I Safety Study in Patients with Severe Hemophilia B (Factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the Gene for Human Factor IX into the Liver.
Principal Investigator: W. Keith Hoots, M.D.,
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Avigen, Inc.
Award Period: 11/13/2001 – 11/12/2005

Pathogenesis of HIV and HCV in Hemophilia: HGDS-3
UTHHSC Principal Investigator: W. Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Children's Hospital, Los Angeles.
Award Period: 09/25/2001-08/31/2005

Second Multi-Center Hemophilia Cohort Study,
UTHHSC Principal Investigator: W. Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Research Triangle Institute
Award Period: 04/01/2001–09/30/2005

General Clinical Research Center CAP Supplement
M01 RR 00046
Funding Agency: NIH-National Center for Research Resources
Principal Investigator: Miguel A. Escobar, M.D.
Funding Period: 07/01/1999–06/30/2004

Inhibitor Development in Hemophilia A is Related to the Genetic Defect and HLA Haplotype. Funding Source: Hemophilia Association of New York, Inc.
Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Hemophilia Association of New York
Award Period: 07/01/2002–06/30/2003

An Open-Label Safety and Efficacy Study of Recombinant Human Factor IX (rFIX: BeneFIX in Previously Treated Patients (PTPS) with Hemophilia B (FIX:C less than/equal to 2%)
Principal Investigator: W. Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Wyeth Pharmaceuticals
Award Period: 03/01/2002–03/31/2003

An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) with Severe Hemophilia A.
Principal Investigator: W. Keith Hoots, M.D.
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Genetics Institute, Inc.
Award Period: 11/20/2001–11/10/2003

Comparison of the Efficacy and Safety of rFVIIa to FEIBA in Hemophilia Patients with Inhibitors Being Treated for Joint Bleeds: An Open-Label, Randomized Study.,
Principal Investigator: W. Keith Hoots, M.D.,
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Novo Nordisk Pharmaceuticals
Award Period: 04/17/2000–04/16/2003

An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX: BeneFIX®) in Children Less than 6 Years of Age with Severe Hemophilia B,
Principal Investigator: W. Keith Hoots, M.D.,
Co-Principal Investigator: Miguel A. Escobar, M.D.
Funding Agency: Genetics Institute/Wyeth-Ayers

Award Period: 12/27/2001–12/31/2002

Phase I Multi-Center Single Treatment Dose Escalation Study of Factor VIII Vector for Treatment of Severe Hemophilia A.

Principal Investigator: Gilbert C. White, II, M.D. (Univ of North Carolina at Chapel Hill)

Co-Investigator, Miguel A. Escobar, M.D.

Funding Agency: Avigen

Funding Period: 1998-2000.

Specificity of Factor IXa Using a Kunitz Type Inhibitor.

Principal Investigator: Harold R. Roberts, M.D. (Univ of North Carolina at Chapel Hill)

Co-Investigator: Miguel A. Escobar, M.D.

Funding Agency: National Institutes of Health

Funding Period: 1997-1999.

An Open Label Study of NOVASTAN in Patients with Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HITTS).

Principal Investigator: Harold R. Roberts, M.D. (Univ of North Carolina at Chapel Hill)

Co-Investigator: Miguel A. Escobar, M.D.

Funding Agency: GlaxoSmithKline

Funding Period: 1997-1998.

Pathogenesis, Susceptibility and Resistance Tropical Medical Research CT grantProject 4

Principal investigator: Nancy G. Saravia, PhD. (CIDEIM)

Co-investigator: Miguel A. Escobar, M.D.

Funding Agency: NIH-NIAID.

Award Period: 1991-1992

Congenital transmission of L. braziliensis and Leishmania chagasi

Principal investigator. Miguel A. Escobar, M.D.

Funding Agency: Fundacion para la Educacion Superior (FES – AID)

Award Period: 1989-1991

Diagnostic value of variables of clinical presentation and epidemiologic history in American Tegumentary Leishmaniasis

Principal investigator: Kristen A. Weigle, M.D (University of North Carolina at Chapel Hill)

Co-investigator: Miguel A. Escobar, M.D.

Funding Agency: IDRC of Canada and NIH of USA.

Award Period: 1989–1990

Infection and disease caused by Leishmania in Colombia: Evaluation of incidence, prevalence and risk factors.

Principal investigator: Kristen A. Weigle, M.D. (University of North Carolina at Chapel Hill)

Co-investigator: Miguel A. Escobar, M.D.

Funding Agency: IDRC of Canada

Award Period: 1989–1990

Abnormal hemoglobins in a black Colombian population.
Principal investigator: Miguel A. Escobar, M.D.
Funding Agency: Universidad Libre, School of Medicine, Cali, Colombia
Award Period: 1984–1985

PUBLICATIONS:

A. ABSTRACTS

Roberts, H.R., **Escobar, M.A.**, Brinkhous, K. Recombinant Factor VIIa. XV International Congress on Haemostasis and Thrombosis, CLAHT. Santo Domingo, Dominican Republic. 1997.

Roberts, H.R., **Escobar, M.A.**, Brinkhous, K. New Concepts in Coagulation. XV International Congress on Haemostasis and Thrombosis. CLAHT, Santo Domingo, Dominican Republic. 1997.

Escobar, M.A., Chang, JY, Roberts, HR and Monroe, DM. Expression of the Second Kunitz Domain of Human Tissue Factor Pathway Inhibitor by a Yeast Expression System. Thrombosis and Haemostasis, 1999; Suppl. a1619.

Escobar, M.A., Roberts, HR. Clinical Experience with the use of recombinant VIIa. XVI International Congress on Haemostasis and Thrombosis. CLAHT, Lima, Peru. 1999.

Ahn Y.S., Cui Y., Horstman L.L., Jy W., **Escobar M.A.** and Bowen B. Chronic platelet activation and progressive vascular dementia in patients with Immune Thrombocytopenic Purpura (ITP). 1st International Congress on vascular dementia. Geneva, Switzerland. 1999.

Ahn Y.S., Horstman L.L., Jy W., Jimenez, J.J., Cui Y., **Escobar M.A.** and Bowen B. Vascular Dementia Among Patients with ITP (Immune Thrombocytopenic Purpura) and Risk Factors. Blood, 2000; 96:a1074.

Escobar, M.A. Advances in Gene Therapy: XVII International Congress on Hemostasis and Thrombosis. CLAHT, Mexico City, Mexico. 2001.

Escobar, M.A., Melton, L.G., Thompson, C.N., Gabriel, D.A. Dose response of Recombinant Factor VIIa in Patients with Hemophilia and Liver Disease. Blood, 2001; 98:a3903.

Escobar, M.A., Harvey, R.D. Experience with the Use of Recombinant Factor VIIa in a University Hospital. Blood, 2001; 98:a3902.

Escobar, M.A. General Clinical Experience with NovoSeven including Experience with High Bolus Dosing. Seville, Spain., World Federation of Hemophilia. May 2002.

Escobar, M.A., Kempton, C, Ma, A. Successful treatment of an autoantibody in congenital hemophilia with Rituximab. *Blood*, 2002;a3915.

Escobar, M., White G.C. Mutation analysis and HLA genotype in patients with inhibitors and hemophilia A. *Journal of Thrombosis and Haemostasis*, 2003; Supplement 1, P0665.

Escobar M, Ulmasov, B., Kuppuswamy, M.N., Bajaj, M.S., Fisher, L, Bajaj, S.P. Congenital factor VII deficiency and thrombosis. Description of a novel mutation. *Journal of Thrombosis and Haemostasis*, 2003; Supplement 1, P1178.

Escobar M.A., Salicru A.N., Hoots W.K., Marshall G.D.. Elevated IgE Associated with Factor VIII Inhibitor Levels in Patients with Hemophilia A. *Blood*, 2003;102:799a.

Salicru A.N., **Escobar M.A.**, Hoots W.K., Marshall G.D.. Elevated IgE associated with factor VIII inhibitor levels in patients with hemophilia A. *The Journal of Allergy and Clinical Immunology*. 2004;113 (Suppl)762.

Planque, S., **Escobar, M.A.**, Taguchi, H., Karle, S., Nishiyama, Y., Donacchie, E., Paul, S. Irreversible blockade of factor VIII antibodies. *Blood*, 2004;104:479a.

Escobar, M.A., Chong, K., Hoots, W.K. Experience with the “off-label” use of recombinant factor VIIa in a university hospital. *Blood*, 2004;104:90b.

Champion H.R., Weiskopf, R., Fingerhut, A., **Escobar, M.A.** Patient safety evaluation in a major trauma clinical trial evaluating a new drug. American Association for the surgery of trauma annual meeting, 2004.

Escobar, M.A., Donnachie, E., Friedrich, U., Hedner, U. Trauma in a non-hemophilic individual. 8th Novo Nordisk Symposium on Haemostasis Management. Copenhagen, Denmark, 2005.

Abdullatif ML, Donnachie E., **Escobar M.A.** Recombinant factor VIIa partially reverses the effects of anticoagulants and antiplatelet agents on thrombin generation and thromboelastography. *Blood*, 2005;106(11):116b.

Souza J.A., **Escobar M.A.** Rituximab as a Treatment Option for Acquired Inhibitors. *Blood* 2006;108(11):95b.

Rodriguez, N.I., Hoots, W.K., Brown, D.L., Womack, M., Cantini, M., **Escobar, M.A.** Failure of Immune Tolerance Induction in Haemophilia B Patients with C, T 6460 Nonsense Mutation. *J Thromb Haemost* 2007; 5 Supplement 2: P-T-130.

Brown, D.L., Donnachie, E., **Escobar, M.**, Rosas, P., Griffin, J., Hoots, W. Sensitivity to Activated Protein C (APC) is Increased During the Secretory Phase of the Menstrual Cycle. *J Thromb Haemost* 2007; 5 Supplement 2: P-S-627.

Smith, K.C., Planque, S., Nishiyama, Y., **Escobar, M.**, Paul, S. A Covalent Reactive Antigen Analog to Factor VIII Reduces Antibody Production in Memory B Cells After Re-stimulation With FVIII. *J Thromb Haemost* 2007; 5 Supplement 2: O-M-063.

Riley, L., Ullman, M., Sayre, D., Hoots, K., and **Escobar. M.**, Assessing Clinical and Demographic Trends in a US Hemophilia Treatment Center Population. XXVIII International Congress of the World Federation of Hemophilia; 2008.14 Supplement 2; 24 PO 24.

Diaz, E., Reyes, A., Murillo, A., Cantini, M., Kuebler, E., **Escobar, M.**. Establishment of a camp for children with bleeding disorders in a developing country. XXVIII International Congress of the World Federation of Hemophilia; 2008.14 Supplement2; 25 PO 10.

Havelli, H., Adejuwon, O., **Escobar, M.A.**, Chong, K., Allison, TA. Recombinant Activated Factor VII for surgical evacuation of subdural hematoma in patients with coagulopathy. *Stroke* 2009.

Laff, S.P., Manco-Johnson, M., Bernstein, J., Cohen, A., DiMichele, D., **Escobar, M.**, et. al. Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult Subjects Compared to That of Episodic Treatment (SPINART). National Hemophilia Foundation Meeting 2009.

Sexauer, C.L., Ayob, Y., Cantini,M., **Escobar, M.A.**; et.al. Absence of Inhibitor Development in the Routine Clinical Use of Alphanate in Patients with Severe Hemophilia A: Results from a Long-Term Post-Marketing Surveillance Study. 2009 American Society of Hematology Annual Meeting, *BLOOD*; 114:22.

Kempton, C.L., Soucie, J.M., Miller, C.H., Hooper, C., **Escobar, M.A.**, et.al. Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study. American Society of Hematology Annual Meeting, 2009 *BLOOD* 114:22.

Nguyen,T, Donnachie,E., Borck,M., Pascual,D., **Escobar,M.**, Smith,K. A Novel Tolerogen Prevents Inhibitor Formation in a Mouse Model of Hemophilia A. American Society of Pediatric Hematology/Oncology 23rd Annual Meeting. *Pediatric Blood and Cancer* 2010, 54(6), 787-864.

Csencsits-Smith. K., Nguyen, T.T., Donnachie,E., Borck,M., **Escobar, M.**, et.al. Effects of a novel mucosal tolerogen on critical T cell cytokine secretion and development of anti-FVIII inhibitor antibody in a mouse model of hemophilia A. *J. Immunol.* 2010, 184:87.27

Paul, S., Planque, S., Nishiyama, Y., Nishiyama, Y., Ghosh, D., **Escobar, M.A.**, and Hanson, C. Revisiting the mostly-conserved CD4 binding site core región as an HIV vaccine target. *AIDS Vaccine* 2010 Conference.

Planque, S., **Escobar, M.**, Nishiyama, Y., and Paul, S. A Protease Resistant Factor VIII Analog for Blockage of Inhibitory Antibodies. 2010 American Society of Hematology Annual Meeting. *BLOOD*; 116(21), 1376.

Martinowitz, U., Shapiro, A., Quon, D., **Escobar, M.**, et.al. Pharmacokinetics of IB1001, a new recombinant Factor IX. *Haemophilia* 2011, 17:27.

Martinovich, U., Lubetsky, A., Shapiro, A., Quon, D., **Escobar, M.**, Kempton, C., et al. "Pharmacokinetic behavior of IB1001, an investigational recombinant Factor IX, in patients with Hemophilia B: repeat pharmacokinetic study and sialylation analysis", 53rd Annual Meeting of the American Society of Hematology, San Diego. December 2011.

Khleif, A, Rodriguez, N., Nguyen, T., Brown D., and **Escobar, MA.** Adherence to Prophylaxis Treatment Regimens among Persons with Severe Hemophilia A and B: Results from a 1-Year, Single Institution Study. XXX International Congress of the World Federation of Hemophilia – July 2012, Paris. France. *Haemophilia* 2012;18(3);162.

Escobar, MA, Chong, K. and Kheif, A. Off-label use of recombinant factor VIIa: results from a 10-year university hospital study. XXIV Congress of the International Society of Thrombosis and Haemostasis. Amsterdam, Netherlands. July 2013

Escobar, MA, Csencsits-Smith. K., Donnachie, E. Early cytokine secretion may predict response to treatment in acquired hemophilia. XXIV Congress of the International Society of Thrombosis and Haemostasis. Amsterdam, Netherlands. July 2013

Escobar, MA, Chong, K. and Kheif, A. Treatment characteristics and associated costs of factor replacement and immunosuppressive therapy among patients with acquired hemophilia A. XXIV Congress of the International Society of Thrombosis and Haemostasis. Amsterdam, Netherlands. July 2013

Smith, K., **Escobar, M.A.**, Donnachie, E. Biomedical Analytics Approach Suggests a Role for TNF Superfamily Signaling In Acquired Hemophilia Patients Who Do Not Respond to Rituximab Treatment. American Society of Hematology Meeting. New Orleans. December 2013.

Khleif A, Gustafson S, Lee M, **Escobar MA.** Assay Management for the Treatment of Hemophilia A and B: Experience from the Gulf States Pharmacy (GSP). XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Gustafson S, Khleif A, **Escobar MA.** Knowledge of Disease and Treatment Understanding among Patients with Hemophilia: Interim Results among Patients Attending the Gulf States Hemophilia and Thrombophilia Center (GSHTC). XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Khleif A, Gustafson S, **Escobar MA.** Factor Assistance Program Utilization: A Follow-Up Study among Patients Attending the Gulf States Hemophilia and Thrombophilia Center

(GSHTC) in Houston, Texas Between 2011 – 2013. XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Escobar M., Austin S., Auerswald G., Millar C., MacDonald S., orton M., and Aldwinckle T: Safety and efficacy of a new high purity factor X concentrate in subjects with factor X deficiency undergoing surgery. XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Samuel S., Allison TA., Yau G., Sharaf S., Mckaig N.,Ranjbar G., Lee K., Nguyen A., Choi HA., **Escobar M.** Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin. Which One to Believe? A Pilot Study. 12th Annual Neurocritical Care Society Meeting, Seattle: Sept 2014.

Sood SL, Cheng D, Shapiro A, Kessler C, Key N, Quon D, Eyster E, **Escobar M**, et al.: A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. American Society of Hematology Annual Meeting. Dec 2014

Escobar M, Colberg T, Karim F, Caliskan U, et al., Peri-operative haemostatic management of major orthopaedic surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX: results from the paradigm™3 clinical trial. XIV International Musculoskeletal Congress WFH. Belfast, Ireland. May 2015

Escobar M, Colberg T, Karim F, Caliskan U, Chowdary P, et al. Perioperative hemostatic management of major surgery in hemophilia B with long-acting recombinant glycopegylated factor IX: results from the paradigm 3 clinical trial. XXV Congress of the International Society of Thrombosis and Haemostasis. Toronto, Canada: June 2015

Escobar M, Auerswald G, Austin S, Huang JN, Norton M, Millar C. Efficacy and safety of pdFX, a new high-purity factor X concentrate, in patients with mild to severe hereditary factor X deficiency undergoing surgery. National Hemophilia Foundation Meeting. Dallas, TX: August 2015

Monahan P, Walsh C, Konkle B, Powell J, Josephson N, **Escobar M.**, et al. Update on a phase ½ open-label trial of BAX 335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. National Hemophilia Foundation 67th Annual Meeting, Dallas, TX: August 2015

Escobar M, Obzut D, Humpries TJ, Afonja O, Detering E. BAY 81-8973: Safety Observations in Clinical Trials in Adults, Adolescents, and Children with Severe Hemophilia A. National Hemophilia Foundation Meeting. Dallas, TX: August 2015

Escobar M, Bond D, Cantini M, Cannon C. A Method for Deriving Pharmacokinetic Constants for Factor VIII and IX from Limited Blood Sampling. American Society of Hematology Annual Meeting. Orlando, FL: December 2015

Young G, **Escobar M**, Pipe S, Lenz S, Cooper D. Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHWI) in the Home Treatment Setting: Systematic Review of Clinical Studies and Registries. American Society of Hematology Annual Meeting. Orlando, FL: December 2015

Escobar M, Young G, Oldenburg J, Mahlangu J, et al. Prophylactic Efficacy of nonacog beta pegol once weekly in adult and pediatric patients with hemophilia B: a pooled analysis. Thrombosis and Hemostasis Summit of North America (THSNA) Meeting. Chicago, IL 2106

Lemons J, Brown D, Cantini M, Cannon K, Rodriguez N, Nguyen T, and **Escobar M**. Genetic variant analysis in children and adults with hemophilia: experience from a large hemophilia center in the US. XXXII International Congress of the World Federation of Hemophilia, Orlando, FL: July 2016

Gustafson S, Lee M, Gonzaga C, and **Escobar MA**. Collecting clinical data through a care management assessment form during telephone patient encounters: A study among patients of the Gulf States Hemophilia and Thrombophilia Center (GSHTC) in Houston, Texas 2014-2015. XXXII International Congress of the World Federation of Hemophilia, Orlando, FL: July 2016

Escobar MA, Smith KC, Donnachie E. Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia. XXXII International Congress of the World Federation of Hemophilia, Orlando, FL: July 2016

Allison T, Hartman H, Gass J, Lin PJ, Chong K, Choi HA and **Escobar M**. Low dose 4-factor Prothrombin Complex Concentrate in reversal of Xa Inhibitors in a Neuro ICU. Critical Care Congress, Honolulu, HI. 2016. and Society of Critical Care Medicine annual Congress— Texas Chapter. Winner of the Alan I. Fields Award. January 2017

B. REFEREED ORIGINAL ARTICLES IN JOURNALS

Escobar, M.A., Duque, H.E., Caicedo, C.H., Barco, H.Z. . Hemoglobinopatías en un grupo étnico negro Colombiano. Colombia Médica, 1988,19(1):34-35.

Martinez, J.E., Arias, A.L., **Escobar, M.A.**, Saravia, N.G. Hemoculture of Leishmania (Viannia) braziliensis from two cases of mucosal leishmaniasis: re- examination of hematogeneous dissemination. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86:392-394.

Weigle, K.A., **Escobar, M.A.**, Arias, A.L., Martinez, F. Rojas, C.A. A clinical prediction rule for American cutaneous leishmaniasis in Colombia. International Journal of Epidemiology, 1993, 21(3):548-558.

Escobar, M.A., Saravia, N.G, Weigle, K.A. Concurrent mucosal Leishmaniasis and Pulmonary Tuberculosis. Clinical Infectious Diseases. 1996, 23(4):836-7.

White, GC 2dn, Greenwood, R., **Escobar, M.**, and Frelinger, J.,A. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective. Haematologica. 2000, 85(10); 113-6.

Depcik-Smith, N.D., **Escobar, M.A.**, Ma, A.D., Brecher, M.E., Red cell rosetting and erythrophagocytosis in adult Paroxysmal Cold Hemoglobinuria. Transfusion. 2001, 1:163.

Escobar, M., Delivery of Treatment for Haemophilia: Report of a joint WHO/WFH/ISTH meeting. World Health Organization, 2002;1-15.

Escobar, M.A. Treatment on demand – in vivo dose finding studies. Haemophilia, 2003;9:360-367.

Escobar M.A., Recombinant Factor VIIa: The possibilities for monitoring. Transfusion Alternatives in Transfusion Medicine. 2003; 5:51-54.

Escobar M.A., Hoots W.K., The use of recombinant factor VIIa in patients undergoing liver transplant. Transfusion Alternatives in Transfusion Medicine. 2003; 5:037-40.

Escobar, M.A. Endpoints in clinical trials involving hemostasis and bleeding. Transfusion. 2005.45:s1:2S-3S.

Astermark, J., Oldenburg, J., **Escobar, M.A.**, White, G.C., Berntorp, E. and the MIBS study group. The Malmo International Brother Study (MIBS)-Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005; 90:924-930.

Champion H.R, Fingerhut, A., **Escobar, M.A.**, Weiskopf, R. The Role of Data and Safety Monitoring in Acute Trauma Resuscitation Research. Journal of the American College of Surgeons. 2007; 204:73-83.

Planque, S., Mitsuda, Y., Taguchi, H., Salas, M., Morris, M.-K., Nishiyama, Y., Kyle, R., Okhuysen, P., **Escobar, M.A.**, Hunter, R., Sheppard, H.W., Hanson, C., Paul, S.. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Research and Human Retroviruses. 2007; 23(12):1541-1553.

Hallevi, H., Gonzales, N.R., Barreto, A.D., Martin-Schild, S., Albright, K.C., Noser, E.A., Illoh, K., Khaja, A.M., Allison, T., **Escobar, M.A.**, Shaltoni, H.M., and Grotta, J.C.. The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond Three Hours vs Within Three Hours. Stroke. 2008; 39(2):473-475.

Hallevi, H., Albright, K.C., Martin-Schild, S., Barreto, A.D., Savitz, S.I., **Escobar, M.A.**, Gonzales, N.R., Noser, E.A., Illoh, Kachi, Grotta, J.C.; On behalf of the VISTA investigators. Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge? Archives of Neurology. 2008 Sep; 65(9):1169-73.

Pivalizza, E.G., **Escobar, M.A.** Thrombelastograph and ROTEM guided Factor VIIa Therapy in a Surgical Patient with Severe Hemophilia and Factor VIII Inhibitor. Anesthesia & Analgesia, 2008; 107(2):398-401.

Marcos, L.A., Majid, R., Hamzeh, Nabeel, Mehta Niraj, **Escobar, M.A.** An Acute Intracerebral Vein Thromboses in AIDS. A Case Report. International Journal of STD and AIDS. 2008;19:59-61.

Planque, S., **Escobar, M.A.**, Smith, KC., Taguchi, H., Nishiyama, Y., Donnachie, E., Pratt, KP., Paul, S. Covalent inactivation of Factor VIII antibodies by an electrophilic FVIII analog. Journal of Biological Chemistry. 2008; 283(18):11876-11886.

Bolliger, D., Szlam, F., Molinaro, R.J., **Escobar, M.A.**, et.al. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Haemophilia 2010; 16(3):510-517.

Escobar, M.A. Health Economics in Haemophilia: A review from the clinician's perspective. Haemophilia 2010; 16 (S3):29-34.

Giagrande, P.L.F., **Escobar, M.A.** Management of difficult-to-treat inhibitor patients. Haemophilia 2010;16(S3):52-57.

Planque, S., Salas, M., Mitsuda, Y., Sienczyk, M., **Escobar, M.A.**, et.al. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010, 24:875-884.

Vaklavas , C., Otelo-Rafiq , EP., Lovy, J., **Escobar, M.A.** and Tsimberidou, AM. Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virology Journal 2010, 7:256:1-5.

Kempton CL, Soucie FM, Miller CH, Hooper C, **Escobar M.A.**, Cohen AJ, Key NS, Thompson AR, and Abshire TC. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010, 8:2224-31.

Chitlur, M., Sorensen, B., Rivard, G.E., Young, G., Ingerslev, G., Othman, M., Nugent, D., Kenet, G., **Escobar, M.A.**, and Lusher., J. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia 2011 , 17: 532-537.

Khleif, A., Rodriguez, N., Brown, D., and **Escobar, M.A.** Multiple Co-morbid Conditions Among Middle-aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care. Journal of Aging Research 2011.

Khleif, A., Rodriguez, N., Brown, D., **Escobar, M.A.** Utilization Patterns and Associated Costs of Factor Assistance Programs among Persons with Hemophilia: A Single Institution Review. Haemophilia. 2012.

Escobar, M.A., Maahs, J, Hellman, E, Donkin, J, Forsyth, A, Hroma, N, et al. Best Practices for the Multidisciplinary Management of Patients with Hemophilia with Inhibitors Undergoing Surgery in the United States. Haemophilia. 2012;18(6):971-81

Martinowitz, U., Shapiro, A., Quon, D.V., **Escobar, M.A.**, et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia. 2012;18(6); 881-7.

Escobar, M.A., Sallah, S. Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis. Journal of Thrombosis and Haemostasis. 2013;11(8); 1449-53.

Santagostino E, **Escobar M**, Ozelo M, Solimeno L, et al. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital hemophilia with inhibitors. Blood Reviews 2015;29S1;S9-S18.

Miller CH, Rice AS, Boylan B, Payne AB, Kelly FM, **Escobar MA**, et al. Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening. Am J Hematol 2015;90(10); 871-6.

Carcao M, Hilliard P, **Escobar M**, Solimeno L, Mahlangu J, Santagostino E. Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol 2015;Suppl 81;11-21.

Escobar MA, G. Auerswald, S. Austin, J. N. Huang, M. Norton and C. M. Millar. Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery. Haemophilia. 2016: DOI: 10.1111/hae.12954

Escobar MA, Tehranchi R, Karim A, Caliskan U, Chowdary P, et al. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia 2016: DOI: 10.1111/hae.13041

Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, **Escobar M**, and Choi HA. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. Journal of Clinical Pharmacy and Therapeutics 2016: 41:499-502. DOI: 10.1111/jcpt.12415

Mahlangu J, Kuliczowski K, Abdul Karim F, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellman A, Santagostino E, Baker RI, Fischer K, Gill JC, P'Ng S, Chowdary P, **Escobar MA**, et al. Efficacy and safety of rVIII-SingleChain: results of a phase I/III multicenter clinical trial in severe hemophilia A. Blood 2016: Blood. 2016 Jun 21. pii: blood-2016-01-687434

Bai, Y., Castillo, BS., Tchakarov, A., **Escobar, MA.**, Cotton, BA., et al. Providing hemostatic and blood conservation options for Jehovah's witness patients in a large medical system. *Annals of Clinical & Laboratory Science* 2016;46:654-661.

C. INVITED ARTICLES (REVIEWS, EDITORIALS, ETC.) IN JOURNALS

Escobar, M.A., Martinez, F., Smith, S., Palma, G. American Cutaneous and Mucocutaneous Leishmaniasis (tegumentary): A Diagnostic Challenge. *Tropical Doctor*, 1992, 22(1): 69-78.

Godley, P.A., **Escobar, M.A.** Renal Cell Carcinoma. *Current Opinion in Oncology*. 1998, 10:261-265.

Roberts, H.R., Monroe, D.M., **Escobar, M.A.** Current concepts of hemostasis: implications for therapy. *Anesthesiology*. 2004;100 (3);722-730.

Kempton, L.K, **Escobar, M.A.**, Roberts, H.R. Hemophilia care in the 21st century and beyond. *Clinical Advances in Hematology & Oncology* 2004, 2 (11); 733-740.

Paul, S., Planque, S., Nishiyama, Y., **Escobar, M.**, Hanson, C., Back to the Future: covalent epitope-based HIV vaccine development. *Expert Review Vaccines* 2010, 9(9); 1027-1043.

Escobar, M.A. Bleeding in the Patient with a Malignancy. *Cancer* 2012, 118(2):312-20.

Rodriguez-Merchan, EC, Rodriguez, NI, **Escobar, M.A.** Total Joint Replacement in Advanced Haemophilic Arthropathy: A Review of Outcome, Complications, Impact of HIV and Inhibitors. *Journal of Clinical Rheumatology & Musculoskeletal Medicine* 2012.

Escobar, M.A. Advances in the Treatment of Inherited Coagulation Disorders. *Haemophilia*. 2013;19(5):648-59.

D. CHAPTERS

Escobar, M.A., Concentrados Purificados en el Tratamiento de la Hemofilia, in *Hemofilia*, CM Murillo, et al. Editors, Editorial Prado, S.A. 2001. pp389-396.

Escobar, M.A., Roberts, H.R. and Ma, A. *Thrombophilia*, in *Pocket Medicine/Internal Medicine*. B.F. Scharschmidt, editor, 2002.

Roberts, H.R. and **Escobar, M.A.**, Other Coagulation Factor Deficiencies in *Thrombosis and Hemorrhage*. Third Edition. J Loscalzo and Al Schafer, Editors. Williams & Wilkins Company. 2002.

Roberts, H.R. and **Escobar, M.A.** Less Common Congenital Disorders of Hemostasis, in Consultative Hemostasis and Thrombosis, CS Kitchens, et al., Editors. W.B. Saunders Company. 2002.

Roberts, HR, **Escobar, M.A.** Other clotting factor deficiencies, in Hematology: Basic Principles and Practice. Fourth Edition. Hoffman R., et al. Editors. Churchill Livingstone. 2005.

Escobar M.A., Products used to treat haemophilia: Dosing, in Textbook of Haemophilia. C Lee, K Hoots and E Berntop, editors. Blackwell Publishing. 2005.

Roberts, H.R., **Escobar, M.A.** White, G.C. Hemophilia A and Hemophilia B, in Williams Hematology. Seventh edition. Beutler E., et al editors. McGraw Hill. 2006.

Roberts, H.R., **Escobar, M.A.** Inherited disorders of prothrombin conversion, in Hemostasis and Thrombosis: basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ et al, editors. Lippincott Williams & Wilkins. Fifth Edition. 2006.

Escobar, M.A., Roberts, H.R. and Ma, A. Thrombophilia, in PocketMedicine/Internal Medicine. B.F. Scharschmidt, editor, 2007.

Roberts, H.R. and **Escobar, M.A.**, Less Common Congenital Disorders of Hemostasis, in Consultative Hemostasis and Thrombosis, CS Kitchens, et al., editors. W.B. Saunders Company. Second Edition 2007.

Escobar, M.A., Diagnosis and Management of Acquired Bleeding Disorders: Vitamin K Antagonists in Evidence- based Hematology, Crowther, M., Ginsberg, J., et al., editors. Blackwell Publishing. 2008.

Roberts, H.R., Key, N., **Escobar, M.A.** Hemophilia A and Hemophilia B, in Williams Hematology. Eighth edition. Beutler E., et al editors. McGraw Hill. 2010.

Escobar M.A., Products used to treat haemophilia: Dosing, in Textbook of Haemophilia. C Lee, K Hoots and E Berntop, editors. Blackwell Publishing. 2010.

Escobar, M.A., and Roberts, H.R. Less Common Congenital Disorders of Hemostasis, in Consultative Hemostasis and Thrombosis, CS Kitchens, et al., editors. W.B. Saunders Company. Third Edition, 2013.

Escobar M.A. Products used to treat haemophilia: Dosing, in Textbook of Haemophilia. C Lee, K Hoots and E Berntop, editors. Blackwell Publishing. 2014.

Escobar, M.A., Nguyen T.T. Hemophilia in Encyclopedia of Human Biology. Willey-Blackwell. 2014.

Escobar, M.A., Key, N. Hemophilia A and Hemophilia B, in Williams Hematology. Ninth edition. Beutler E., et al editors. McGraw Hill. 2016.

Escobar, M.A., Nguyen T.T. Known bleeding disorders for surgery in Management of Bleeding Patients. J. Teruya, editor. Springer 2016.

E. BOOKS

Ma, DA., Roberts, HR., **Escobar, MA.** Hemophilia and Hemostasis: A Case-Based Approach to Management. Willey-Blackwell 2012. Second Edition.

F. OTHER PROFESSIONAL COMMUNICATIONS

1. Presentations

07/1997 1) "Recombinant Factor VIIa", 2) "New Concepts in Coagulation", XV International Congress on Haemostasis and Thrombosis, CLAHT. Santo Domingo, Dominican Republic.

06/1999 "Clinical Experience with the use of recombinant VIIa", XVI International Congress on Haemostasis and Thrombosis. CLAHT, Lima, Peru.

09/2001 "Advances in Gene Therapy: Myths and Reality", XVII International Congress on Hemostasis and Thrombosis. CLAHT, Mexico City, Mexico.

02/2001 "Treatment on demand – in vivo dose finding studies" Delivery of Treatment for Haemophilia: WHO/WFH/ISTH meeting in London UK.

05/2002 "General Clinical Experience with NovoSeven including Experience with High Bolus Dosing". Seville, Spain., World Federation of Hemophilia.

09/2002 "Tromboembolismo Venoso", "Inhibidores en Hemofilia" First International Meeting on Thrombosis and Coagulation, Santo Domingo, Dominican Republic

11/2002 "Mechanisms and Pathophysiology: Coagulopathy of Liver Disease and Treatment Options", 53rd American Association for the Study of Liver Diseases (AASLD) Annual Meeting, Boston, MA

11/2002 1) "Haemophilia and Inhibitors: Bleeding Prophylaxis in Surgery", 2) "Inhibitors in Congenital and Acquired Haemophilia: Treatment of Bleedings, 3) "Safety Issues with the Use of NovoSeven®", Second Symposium on Hemophilia and Inhibitors, São Paulo, Brazil

01/2003 "Alternative Medicine and Hematological Risks", Region VI Hemophilia Annual Meeting, Oklahoma City, OK

09/2003 "Alternative Medicine", Women w/Bleeding Disorders Camp, Burton, TX

10/2003 1) "Revisiting the Coagulation Cascade - Simplifying the Complex", 2) "New Approaches to the Treatment of the Bleeding Patient", 3rd Annual Southwest Symposium and Thrombosis, Hemostasis & Transfusion Medicine , Albuquerque, NM

08/2004 1) "Overview of Thrombophilia", 2) "Post-Thrombotic Syndrome" Region VI Hemophilia Nursing/Psychosocial Midyear Conference, Galveston, TX

08/2004 1) "Conceptos Actuales de Hemostasia", 2) "Qué es Factor VIIa Recombinante Experiencia en Hemofilia" , 3)"Otras Indicaciones y uso potencial de NovoSeven®", CLAHT Meeting (Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis), Peru

09/2004 1) "New Concepts of Coagulation", 2)"Other Alternative for the Treatment of Surgical Bleeding", 1st Hemostasis Symposium on Novel Agents, Colombia and Venezuela

09/2004 "Recombinant Activated Factor VII: Present and Future", Society for the Advancement of Blood Management, Miami, FL

05/2005 "Off-Label use of rFVIIa", Hemophilia Alliance Meeting, Denver, CO

05/2005 "Treatment Strategies for Rare Congenital Bleeding Disorders", Updated Treatment Strategies: Rare Bleeding Disorders and Critically ill Patients Symposium, American Society of Pediatric Hematology/Oncology, Washington, DC

07/2005 1) "Fisiología de la coagulación, nuevos adelantos y fusión de teorías", 2) "Manejo de Inhibidores en el hemofílico", II Simposio latinoamericano sobre el Manejo Integral del Paciente Hemofílico, Bogota, Colombia

11/2005 1) "Acquired Inhibitors to Factor VIII", 2) "Recombinant Factor VIIa in the Treatment of Glanzmann Thrombastenia and Congenital Factor VII Deficiency", 3) Prophylaxis in Patients with Inhibitors", National Brazilian Hematology Congress in Rio de Janeiro

11/2005 "Inhibitors in Hemophilia", XIX International Congress on Hemostasis and Thrombosis CLAHT, Chile

03/2006 1) "Nuevos conceptos de coagulación", 2) "Directrices de la FMH para el tratamiento del paciente con hemofilia", 3) "Transfusiones: Riesgos y contaminación", 4) "Inhibidores: Aspectos Generales", 5) "Diagnostico y manejo de portadoras, World Federation of Hemophilia Meeting, Quito, Ecuador

10/2006 "The role of Recombinant FVIIa in Critical Bleeding". Hematology Association of Venezuela Meeting. Caracas, Venezuela.

- 10/2006 “The role of Recombinant FVIIa in Critical Bleeding”. XVIII National Anesthesiology Meeting. Barquisimeto, Venezuela.
- 11/2006 “Making Treatment Choices in Hemophilia”, Mt. Sinai Medical Center, New York. Hemophilia Patient Association.
- 11/2006 “Success Through the Years in Hemophilia”, El Paso, TX. Hemophilia Patient Association
- 03/2007 “Acquired Hemophilia – a diagnostic and therapeutic challenge”. XXXI World Congress of the International Society of Hematology. Punta del Este, Uruguay.
- 05/2007 “Management of Critical bleeding”. V Congreso Grupo Cooperativo Iberoamericano de Medicina Transfusional GCIAMT”. San Jose, Costa Rica.
- 05/2007 “Treatment of Hemophilia: the benefits of recombinant products”. XLVIII Congreso Annual de la Agrupacion Mexicana para el Estudio de la Hematologia. Acapulco, Mexico.
- 08/2007 “Viral Risks and Thrombotic Complications of Coagulation factors” and “Treatment of Hemorrhagic Episodes in Patients with Hemophilia”. Universidad Latinoamericana de la Hemofilia. Buenos Aires, Argentina.
- 10/2007 “New Approaches in the Diagnosis and Treatment of Acquired Hemophilia”. Recent Advances in Managing Bleeding Disorders Symposium. Formosa Association for the Surgery of Trauma. Taipei, Taiwan.
- 11/2007 “Past, Present and Future: GSHTC and Hospital Infantil Benjamin Bloom Twining Program”. World Federation of Hemophilia Twining Program. El Salvador.
- 10/2008 “Inhibitors in hemophilia”; “Prophylaxis in patient with hemophilia”; “Management of critical bleeding in patients without congenital hemophilia”. Primera Reunion Centroamericana y del Caribe: Cambiando las Posibilidades en Hemofilia. CLOTTING group annual hemostasis meeting. Panama City, Panama.
- 11/2008 “Cuando utilizar los nuevos anticoagulantes”; “El uso del Factor VIIa recombinante en condiciones diferentes a la hemofilia”. Primer Congreso Nacional de Medicina Interna Basada en la Evidencia. Instituto de Investigaciones Fundacion Universitaria Sanitas. Bogota, Colombia.
- 01/2009 “Review on Bleeding Disorders”. I Dental Symposium on Patients with Bleeding Disorders. Hospital Pediatrico Benjamin Bloom. El Salvador.
- 01/2009 “New Concepts in Hemostasis”. Pediatric Grand Rounds. Hospital Pediatrico Benjamin Bloom, El Salvador.

04/2009 1)"Acquired Haemophilia: Treatment Options and 2) Management of Mild to Moderate Bleeding with Inhibitors". 3rd Asian Regional Hemostasis Update 2009. Kuala Lumpur, Malaysia.

04/2009 "Reversal of anticoagulants". IV. ROTEM Expert-Meeting. Landshut, Germany.

05/2009 1)"Acquired Hemophilia", 2)"Plasmatic Concentrates vs Recombinant in Inhibitors Development". VIII Latin American Meeting in Hematology, Immunology and Transfusion Medicine, II International Symposium on Regenerative Medicine; III International Hemophilia Workshop and VI Cuban Congress of Hematology. La Habana, Cuba.

07/2009 "Diagnostico y tratamiento del paciente que desarrolla inhibidor". Congreso Anual de la Federacion de Hemofilia de la Republica Mexicana, A.C. Monterrey, Mexico.

09/2009 "Health Economics: A review from the Clinician's Perspective". 10th Novo Nordisk Symposium on Haemostasis Management. Prague, Czech Republic.

10/2009 "Bleeding disorders 101 or Understanding Your Diagnosis" and "Comprehensive care from a cultural perspective: The Latino Patient" at National Hemophilia Foundation 61st Annual Meeting, San Francisco, CA.

03/2010 "Hemostasis in Cardiovascular Surgery" at The Houston Aortic Symposium: Frontiers in Cardiovascular Diseases, the Third in the Series. Houston, TX.

04/2010 "Alternative Medicine", Women w/Bleeding Disorders Camp, Navasota, TX.

11/2010 "Hemophilia and Inhibitors", Pediatric Grand Rounds. Hospital Pediatrico Benjamin Bloom, El Salvador.

03/2011 "Immune Tolerance Induction in Hemophilia" and "Aging in Hemophilia"; 10th NovoSeven Symposium, Buenos Aires, Argentina.

05/2011 "Immune Tolerance in Hemophilia" and "Multidisciplinary Management of Hemophilia". World Federation of Hemophilia Meeting. San Pedro Sula, Honduras.

08/2011 "Prophylaxis in Hemophilia". Mexican Society of Hematology. Mexico City.

11/2012 "Heparin Induced Thrombocytopenia", "New Anticoagulants". Colombian National Hematology/Oncology Meeting. Medellin, Colombia.

11/2012 “Sugar and Spice and not Everything Nice: Alternative Medicine and Bleeding Disorders”, National Hemophilia Foundation 64th Annual Meeting, Orlando, FL

01/2013 “Prophylaxis in Hemophilia”. Mexican Hemophilia Society. Mexico City.

06/2013 “Management of Patients with inhibitors” and “Prophylaxis in Hemophilia”. Dominican Republic National Hematology Congress.

10/2013 “The Obesity Epidemic: Weight Management, Bariatric Surgery & Related Cosmetic Surgery” and “Aging: Comorbidities and Bleeding Disorders, National Hemophilia Foundation 65th Annual Meeting, Anaheim, CA.

10/2013 “Inhibitors in Hemophilia A and B. Acute Treatment and Immune Tolerance is a good solution?” and “Differences Between Hemophilia A and B”. XXIII International Congress on Hemostasis and Thrombosis CLAHT, Cancun, Mexico.

07/2014 “Hemophilia Care in Developed Countries”. Central American and Caribbean Leadership Forum in Hemophilia. Panama City, Panama.

09/2014 “Ask the Experts: inhibitors in Hemophilia”, National Hemophilia Foundation 66th Annual Meeting, Washington, DC.

10/2014 “New Concepts in Coagulation”, “Update on Coagulation Assays. More Than Just PT/PTT”, “Emerging Coagulation Factors for Hemophilia”, “Prophylaxis in Hemophilia”. 3rd National Update on Hematology/Oncology. Cali, Colombia.

03/2015 “DIC, Bleeding Disorders and Coagulopathy”. 3rd Annual Neuro ICU Symposium. Houston, TX.

08/2015 “One in a Million: Rare Bleeding Disorders” and “Rare Bleeding Disorders”, National Hemophilia Foundation 67th Annual Meeting, Dallas, TX.

08/2015 “Management of Comorbidities in Hemophilia and vonWillebrand Disease”, XXIV CLAHT Group International Congress. Sao Paulo, Brazil.

09/2015 “New Methods to Predict the Immunogenicity of Therapeutic Coagulation Proteins”. National Institute of Health Public Workshop. Panelist. Bethesda, Maryland.

10/2015 “Management of other comorbidities in hemophilia”, XIII Congreso Venezolano de Hematología. Caracas, Venezuela (web-conference).

07/2016 “Ask the Experts: inhibitors in Hemophilia”, National Hemophilia Foundation 68th Annual Meeting, Orlando, FL.

09/2016 Hemophilia Care in Developed Countries”. Central and South American Leadership Forum in Hemophilia. Lima, Peru.

2. Non-refereed Publications

Brisco, A.D. Lange Q&A. USMLE Step 3. McGraw-Hill. Fourth and Fifth Editions 2005, 2007. Contributor.

3. Scientific Exhibits/Oral presentations

Roberts, H.R., **Escobar, M.A.**, Brinkhous, K. Recombinant Factor VIIa. XV International Congress on Haemostasis and Thrombosis, CLAHT. Santo Domingo, Dominican Republic. 1997.

Roberts, H.R., **Escobar, M.A.**, Brinkhous, K. New Concepts in Coagulation. XV International Congress on Haemostasis and Thrombosis. CLAHT, Santo Domingo, Dominican Republic. 1997.

Escobar, M.A., Chang, JY, Roberts, HR and Monroe, DM. Expression of the Second Kunitz Domain of Human Tissue Factor Pathway Inhibitor by a Yeast Expression System. Thrombosis and Haemostasis, 1999

Escobar, M.A., Roberts, HR. Clinical Experience with the use of recombinant VIIa. XVI International Congress on Haemostasis and Thrombosis. CLAHT, Lima, Peru. 1999.

Escobar, M., White G.C. Mutation analysis and HLA genotype in patients with inhibitors and hemophilia A. International Society of Thrombosis and Haemostasis, Meeting. Birmingham, UK, 2003.

Escobar M, Ulmasov, B., Kuppuswamy, M.N., Bajaj, M.S., Fisher, L, Bajaj, S.P. Congenital factor VII deficiency and thrombosis. Description of a novel mutation. . International Society of Thrombosis and Haemostasis, Meeting. Birmingham, UK, 2003

Escobar M.A., Salicru A.N., Hoots W.K., Marshall G.D.. Elevated IgE Associated with Factor VIII Inhibitor Levels in Patients with Hemophilia A. American Society of Hematology Meeting, 2003.

Planque, S., **Escobar, M.A.**, Taguchi, H., Karle, S., Nishiyama, Y., Donnachie, E., Paul, S. Irreversible blockade of factor VIII antibodies. American Society of Hematology Meeting, 2004.

Champion H.R., Weiskopf, R., Fingerhut, A., **Escobar, M.A.** Patient safety evaluation in a major trauma clinical trial evaluating a new drug. American Association for the surgery of trauma annual meeting 2004.

Escobar, M.A., Donnachie, E., Friedrich, U., Hedner, U. Trauma in a non-hemophilic individual. Abstract/poster. Presented at the 8th Novo Nordisk Symposium on Haemostasis Management. Copenhagen, Denmark. 2005.

Planque, S., Mitsuda, Y., Taguchi, H., Salas, M., Morris, MK., Nishiyama, Y., Kyle, R., Okhuysen, P., **Escobar, MA.**, Hunter, R., Sheppard, HW., Hanson, C. and Paul S. Naturally Occurring Catalytic IgAs: Protective Anti-HIV Mediators? Presented at the Center for AIDS Research Retreat. Baylor College of Medicine, Houston 2006

Smith, K.C., Planque, S., Nishiyama, Y., Taguchi, H., **Escobar, M.**, and Paul, S. Pretreatment of CD138- B Lymphocytes with a Covalent Reactive Antigen Analog to Factor VIII Reduces Antibody Production in response to FVIII. 94th Annual Meeting, The American Association of Immunologists, May 18-22, 2007; Miami, FL,.

Smith, K.C., Planque, S., Nishiyama, Y., **Escobar, M.**, Paul, S. A Covalent Reactive Antigen Analog to Factor VIII Reduces Antibody Production in Memory B Cells After Re-stimulation With FVIII. XXI Congress of the International Society of Haemostasis and Thrombosis, July 6-12, 2007; Geneva Switzerland. (oral presentation).

Rodriguez, N.I., Hoots, W.K., Brown, D.L., Womack, M., Cantini, M., **Escobar, M.A.** Failure of Immune Tolerance Induction in Haemophilia B Patients with C, T 6460 Nonsense Mutation. XXI Congress of the International Society of Haemostasis and Thrombosis, July 6-12, 2007; Geneva Switzerland.

Riley, L., Ullman, M., Sayre, D., Hoots, K., and **Escobar. M.**, Assessing Clinical and Demographic Trends in a US Hemophilia Treatment Center Population. XXVIII International Congress of the World Federation of Hemophilia; June 2008: Istanbul, Turkey.

Diaz, E., Reyes, A., Murillo, A., Cantini, M., Kuebler, E., **Escobar, M.** Establishment of a camp for children with bleeding disorders in a developing country. XXVIII International Congress of the World Federation of Hemophilia; June 2008. Istanbul, Turkey.

Havelli, H., Adejuwon, O., **Escobar, M.A.**, Chong, K., Allison, TA. Recombinant Activated Factor VII for surgical evacuation of subdural hematoma in patients with coagulopathy. International Stroke Conference; February 2009. San Diego, California.

Laff, PL., Manco-Johnson, M., Bernstein, J., Cohen A., DiMichele, D., **Escobar, M.A.**, et al. Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult subjects compared to that of episodic treatment (SPINART). National Hemophilia Foundation 61th annual meeting. 2009. San Francisco, California.

Planque, S., **Escobar, M.A.**, Nishiyama, Y., Paul, S. A Protease Resistant Factor VIII Analog for Blockade of Inhibitory Antibodies. 52nd Annual Meeting of the American Society of Hematology; December, 2010. Orlando, Florida.

Martinovich,U., Lubetsky, A., Shapiro, A., Quon, D., **Escobar, M.A.**, Kempton, C., et al.“Pharmacokinetic behavior of IB1001, an investigational recombinant Factor IX, in patients with Hemophilia B: repeat pharmacokinetic study and sialylation analysis”, 53rd Annual Meeting of the American Society of Hematology December 2011, San Diego, CA.

Khleif, A, Rodriguez, N., Nguyen, T., Brown D., and **Escobar, M.A.** Adherence to Prophylaxis Treatment Regimens among Persons with Severe Hemophilia A and B: Results from a 1-Year, Single Institution Study. XXX International Congress of the World Federation of Hemophilia – July 2012, Paris. France. Haemophilia 2012;18(3);162.

Escobar, M.A., Chong, K and Kheif, A. Off-label use of recombinant factor VIIa: results from a 10-year university hospital study. XXIV Congress of the International Society of Thrombosis and Haemostasis. Amsterdam, Netherlands. July 2013

Escobar, M.A., Csencsits-Smith. K, Donnachie,E. Early cytokine secretion may predict response to treatment in acquired hemophilia. XXIV Congress of the International Society of Thrombosis and Haemostasis. Amsterdam, Netherlands. July 2013

Escobar, M.A., Chong, K and Kheif, A. Treatment characteristics and associated costs of factor replacement and immunosuppressive therapy among patients with acquired hemophilia A. XXIV Congress of the International Society of Thrombosis and Haemostasis. Amsterdam, Netherlands. July 2013

Smith, K., **Escobar, MA**, Donnachie, E. Biomedical Analytics Approach Suggests a Role for TNF Superfamily Signaling In Acquired Hemophilia Patients Who Do Not Respond to Rituximab Treatment. American Society of Hematology Meeting. New Orleans. December 2013.

Khleif A, Gustafson S, Lee M, **Escobar MA**. Assay Management for the Treatment of Hemophilia A and B: Experience from the Gulf States Pharmacy (GSP). XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Gustafson S, Khleif A, **Escobar MA**. Knowledge of Disease and Treatment Understanding among Patients with Hemophilia: Interim Results among Patients Attending the Gulf States Hemophilia and Thrombophilia Center (GSHTC). XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Khleif A, Gustafson S, **Escobar MA**. Factor Assistance Program Utilization: A Follow-Up Study among Patients Attending the Gulf States Hemophilia and Thrombophilia Center (GSHTC) in Houston, Texas Between 2011 – 2013. XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Escobar M., Austin S., Auerswald G., Millar C., MacDonald S., Orton M., and Aldwinckle T: Safety and efficacy of a new high purity factor X concentrate in subjects with factor X deficiency undergoing surgery. XXXI International Congress of the World Federation of Hemophilia, Melbourne, Australia: May 2014.

Samuel S., Allison,TA., Yau G., Sharaf S., Mckaig N.,Ranjbar G., Lee K., Nguyen A., Choi HA., **Escobar M.** Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin. Which One to Believe? A Pilot Study. 12th Annual Neurocritical Care Society Meeting, Seattle: Sept 2014.

Experience of FACTOR X, a New High Purity Factor X Concentrate in Subjects with Factor X Deficiency Undergoing Surgery. **Escobar M**, Auerswald G, Austin S, et al. Hemostasis & Thrombosis Research Meeting, New Orleans, LA: April 2015

Escobar M, Colberg T, Karim F, Caliskan U, Chowdary P, et al. Perioperative hemostatic management of major surgery in hemophilia B with long-acting recombinant glycopegylated factor IX: results from the paradigm 3 clinical trial. XXV Congress of the International Society of Thrombosis and Haemostasis. Toronto, Canada: June 2015

Escobar M and Donnachie E. Comparison of different coagulation assays for the management of acquired hemophilia. XXV Congress of the International Society of Thrombosis and Haemostasis. Toronto, Canada: June 2015

Escobar M, Chandra S, Wilson E, Chong K. Mild hemophilia A complicated by inhibitor after surgery and factor replacement therapy. XXV Congress of the International Society of Thrombosis and Haemostasis. Toronto, Canada: June 2015

Monahan P, Walsh CE, Powell JS, Konkle BA, Josephson NC, **Escobar M.**, et al. Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. XXV Congress of the International Society of Thrombosis and Haemostasis. Toronto, Canada: June 2015

Escobar M, Obzut D, Humpries TJ, Afonja O, Detering E. BAY 81-8973: Safety Observations in Clinical Trials in Adults, Adolescents, and Children with Severe Hemophilia A. National Hemophilia Foundation Meeting. Dallas, TX: August 2015

Sood SL,Cheng D, Shapiro A, Kessler C, Key N, Quon D, Eyster E, Manco-Johnson M, Kempton C, Fogarty P, Ragni M, Gill J, Kuriakose P, von Drygalski A, Kouides P, **Escobar, M**, et. al. A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. American Society of Hematology Annual Meeting. Orlando, FL: December 2015

Escobar M, Bond D, Cantini M, Cannon C. A Method for Deriving Pharmacokinetic Constants for Factor VIII and IX from Limited Blood Sampling. American Society of Hematology Annual Meeting. Orlando, FL: December 2015

Young G, **Escobar M**, Pipe S, Cooper D. Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHWI) in the Home Treatment Setting: Systematic Review of Clinical Studies and Registries. American Society of Hematology Annual Meeting. Orlando, FL: December 2015

Escobar M, Young G, Oldenburg J, Mahlangu J, et al. Prophylactic Efficacy of nonacog beta pegol once weekly in adult and pediatric patients with hemophilia B: a pooled analysis. Thrombosis and Hemostasis Summit of North America (THSNA) Meeting. Chicago, IL 2106

Lemons J, Brown D, Cantini M, Cannon K, Rodriguez N, Nguyen T, and **Escobar M**. Genetic variant analysis in children and adults with hemophilia: experience from a large hemophilia center in the US. XXXII International Congress of the World Federation of Hemophilia, Orlando, FL: July 2016

Gustafson S, Lee M, Gonzaga C, and **Escobar MA**. Collecting clinical data through a care management assessment form during telephone patient encounters: A study among patients of the Gulf States Hemophilia and Thrombophilia Center (GSHTC) in Houston, Texas 2014-2015. XXXII International Congress of the World Federation of Hemophilia, Orlando, FL: July 2016

Escobar MA, Smith KC, Donnachie E. Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia. XXXII International Congress of the World Federation of Hemophilia, Orlando, FL: July 2016

Allison T, Hartman H, Gass J, Lin PJ, Chong K, Choi HA and **Escobar M**. Low dose 4-factor Prothrombin Complex Concentrate in reversal of Xa Inhibitors in a Neuro ICU. Critical Care Congress, Honolulu, HI. 2016. and Society of Critical Care Medicine annual Congress— Texas Chapter. Winner of the Alan I. Fields Award. January 2017